Physician profile
Chitra Raghavan
NPI 1376603738
$6,003.21
in general payments reported to CMS, 2019-2025
46 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $712 · 2021: $898 · 2022: $767 · 2023: $1,410 · 2024: $1,121 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,290.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,301.65 | 2020-2025 | |
| Pfizer INC. | $695.85 | 2019-2025 | |
| Lilly USA, LLC | $471.97 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $382.74 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $347.12 | 2019-2025 | Wegovy |
| Astellas Pharma US INC | $337.68 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.80 | 2019-2023 | Ofev, Jardiance |
| Amgen INC. | $301.85 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $169.46 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $146.64 | 2023-2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $145.59 | 2024-2025 | Fanapt |
| Abbott Laboratories | $138.06 | 2019-2024 | Cardiomems, Freestyle Libre 3, Freestyle Libre 2 |
| Sirtex Medical INC | $128.01 | 2023 | Sir-Spheres Microspheres |
| Janssen Pharmaceuticals, INC | $109.53 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $101.36 | 2023-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Raghavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.